Compare TFX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | BLTE |
|---|---|---|
| Founded | 1943 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 1994 | 2021 |
| Metric | TFX | BLTE |
|---|---|---|
| Price | $133.76 | $145.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $138.75 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 444.7K | 201.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,992,713,000.00 | N/A |
| Revenue This Year | $15.97 | N/A |
| Revenue Next Year | $5.15 | $492.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $100.18 | $57.99 |
| 52 Week High | $139.67 | $200.00 |
| Indicator | TFX | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 49.92 |
| Support Level | $118.39 | $132.50 |
| Resistance Level | $136.14 | $151.41 |
| Average True Range (ATR) | 3.95 | 7.43 |
| MACD | 0.46 | 0.71 |
| Stochastic Oscillator | 96.05 | 49.80 |
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.